<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Mark one)
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the quarterly period ended March 31, 1998.
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the transition period from _______________ to
_______________.
Commission File Number
0-19290
COR THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 94-3060271
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
256 East Grand Avenue, South San Francisco, California 94080
(Address of principal executive offices and zip code)
(650) 244-6800
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.
Common Stock $.0001 par value 24,088,791
----------
Outstanding at April 30, 1998
1
<PAGE> 2
COR THERAPEUTICS, INC.
PART II. OTHER INFORMATION
Item 1. Legal proceedings. Note 2 of the Notes to Financial Statements is
incorporated by reference in Part II hereof.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
27.1 Financial Data Schedule.(1)
(b) Reports
There were no reports on Form 8-K filed for the quarter ended
March 31, 1998.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: July 23, 1998
COR THERAPEUTICS, INC.
By: /s/ VAUGHN M. KAILIAN By: /s/ LAURA A. BREGE
---------------------------- -----------------------------
Vaughn M. Kailian Laura A. Brege
President and Chief Executive Officer Senior Vice President, Finance
and Chief Financial Officer
By: /s/ PETER S. RODDY
------------------------------
Peter S. Roddy
Director, Finance and Controller
(1) This 10-Q/A corrects an error by the Filing Agent in the transmission of
Exhibit 27.1, Financial Data Schedule. There are no other changes to the
Report on form 10-Q as previously filed.
11
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED BALANCE SHEETS, STATEMENTS OF OPERATIONS, AND STATEMENTS OF CASH FLOWS
INCLUDED IN THE COMPANY'S FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 1998 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS AND THE
NOTES THERETO.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> MAR-31-1998
<CASH> 19,937
<SECURITIES> 58,022
<RECEIVABLES> 832
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 87,348
<PP&E> 23,142
<DEPRECIATION> (18,231)
<TOTAL-ASSETS> 92,259
<CURRENT-LIABILITIES> 15,709
<BONDS> 0
0
0
<COMMON> 2
<OTHER-SE> 73,904
<TOTAL-LIABILITY-AND-EQUITY> 92,259
<SALES> 0
<TOTAL-REVENUES> 8,412
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 14,695
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 140
<INCOME-PRETAX> (5,276)
<INCOME-TAX> 0
<INCOME-CONTINUING> (5,276)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,276)
<EPS-PRIMARY> (0.22)
<EPS-DILUTED> (0.22)
</TABLE>
